 |
Tranzyme’s business strategy is to use its unique, proprietary chemistry
to discover breakthrough therapeutics for high-value, intractable drug targets,
and to develop drugs which address diseases with significant unmet medical need.
Tranzyme’s strategy is to license certain rights to these drugs when proof of
concept in man is achieved, or when a program may benefit from the research,
development and commercialization capabilities of a partner. Through these
strategic partnerships, Tranzyme intends to balance risk while preserving
the potential for significant returns.
Tranzyme is interested in initiating partnership discussions on
the following programs:
|
TZP-101 for severe GI motility disorders |
 |
TZP-101 is a potent ghrelin agonist currently in Phase IIb
clinical trials for two distinct indications: post-operative ileus (POI) and severe gastroparesis.
In preclinical studies, TZP-101 has demonstrated the ability to rapidly restore gastrointestinal
function impaired by surgery, opioids and high caloric meals. In both single-dose and multi-dose
Phase I studies, TZP-101 has been demonstrated to be safe and well-tolerated in healthy subjects.
A proof of concept (Phase IIa) clinical trial has been completed. In this double-blind, randomized,
four-way crossover study, TZP-101 significantly accelerated gastric emptying and relieved the
symptoms of gastroparesis.
Phase IIb trials of TZP-101 for POI and severe gastroparesis are currently underway. These multi-center,
randomized, double-blind, placebo-controlled, dose-ranging studies will assess the efficacy and safety of
TZP-101 in patients undergoing major open abdominal surgery (POI), and patients with severe gastroparesis.
Tranzyme expects to have data available from both of these trials in the first quarter of 2008.
|
TZP-102 for gastroparesis and other functional GI disorders |
|
TZP-102 is a second generation oral ghrelin agonist in development for mild-to-moderate gastroparesis. TZP-102 is particularly well-suited for long-term oral therapy required
by the chronic nature of gastroparesis. In addition to gastroparesis, TZP-102 can also
be developed for other functional GI disorders such as functional dyspepsia, GERD, and
opioid bowel dysfunction.
Tranzyme expects to file an IND for TZP-102 by December, 2007.
|
TZP-201 for moderate-to-severe diarrhea |
|
TZP-201 is a motilin antagonist currently in the preclinical
efficacy profiling and drug development stage. The initial targeted indications for
TZP-201 are chemotherapy-induced diarrhea, diarrhea associated with infection,
and diarrhea associated with irritable bowel syndrome. Tranzyme is interested
in initiating partnering discussions with companies that wish to expand their
product portfolios in the oncology supportive care and anti-infective disease areas.
Tranzyme expects to file an IND for TZP-201 by the third quarter of 2008.
|
Chemistry-Based Drug Discovery |
|
Tranzyme Pharma has developed its product portfolio using its breakthrough,
proprietary macrocyclic small molecule chemistry technology. These macrocyclic small molecules have
many distinct advantages over other drug discovery approaches: agonists as well as antagonists can be
developed, synthesis is simple, cost of goods is low, and good PK, ADME, and oral bioavailability
properties can be easily developed. Drug target classes of particular interest are GPCRs, proteases,
kinases, ion channels and protein-protein interaction targets.
Tranzyme is seeking to complement its product portfolio with chemistry-based drug discovery partnerships.
Our chemistry program business strategy is to enter into high-value partnerships with leading pharmaceutical
and biotechnology companies in which Tranzyme contributes this chemistry technology, and its extensive
discovery chemistry and medicinal chemistry expertise, and the partner contributes the drug targets,
drug target biology and expertise in the target area These collaborations will allow the partner to
develop many promising drug leads, and provide a significant competitive advantage in its field
using this breakthrough chemistry technology.
To discuss these opportunities, please contact Tranzyme’s Business Development Department:
Eric M. Nelson, Ph.D.
Vice President, Business Development & Licensing
enelson@tranzyme.com
Phone: (919) 313-4759
|
|
|
